Usefulness of radium-223 in patients with bone metastases
Nishant Gupta1, Arushi Devgan1, Itisha Bansal1
1Department of Radiology, Columbia University Medical Center, New York, New York (Gupta); Department of Radiology, University of Arkansas, Little Rock, Arkansas (Devgan); Department of Anesthesiology, New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York (Bansal); Department of Nuclear Medicine, St. Vincent's Medical Center, Bridgeport, Connecticut (Olsavsky); Department of Radiology, Yale New Haven Health at Bridgeport Hospital, Bridgeport, Connecticut (Li, Abdelbaki); and Columbia University at Bassett Healthcare, Cooperstown, New York (Kumar).
Abstract:
Castration-resistant prostate osseous metastases can be challenging to treat. There is a new era of clinical advancement with the Food and Drug Administration approval of radium-223 for use in these patients. Radium-223 is the only clinically used therapeutic radiopharmaceutical that emits alpha particles, making it extremely safe for therapeutic purposes for the patient as well as close contacts. This review discusses radium-223's mechanism of action, pharmacokinetics, indications, and safety profile, as well as findings of concluded clinical trials.
More Related Videos
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
07:15Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
Published on: August 16, 2020
